Repligen Corporation $RGEN Stock: E. Ohman J or Asset Management AB Reduces Position

by · The Cerbat Gem

E. Ohman J or Asset Management AB lessened its holdings in Repligen Corporation (NASDAQ:RGEN – Free Report) by 12.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 24,980 shares of the biotechnology company’s stock after selling 3,620 shares during the period. E. Ohman J or Asset Management AB’s holdings in Repligen were worth $4,802,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. United Capital Financial Advisors LLC acquired a new position in shares of Repligen in the second quarter worth $380,756,000. Wasatch Advisors LP raised its stake in Repligen by 27.9% during the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after acquiring an additional 346,720 shares in the last quarter. Maverick Capital Ltd. purchased a new stake in Repligen in the first quarter valued at approximately $178,946,000. Conestoga Capital Advisors LLC grew its position in Repligen by 3.8% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,097,783 shares of the biotechnology company’s stock worth $129,341,000 after purchasing an additional 39,808 shares during the last quarter. Finally, Congress Asset Management Co. boosted its stake in shares of Repligen by 0.9% during the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company’s stock worth $196,249,000 after buying an additional 8,681 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on RGEN. Weiss Ratings raised shares of Repligen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Wells Fargo & Company upped their price objective on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Evercore reaffirmed an “outperform” rating and set a $160.00 price target on shares of Repligen in a research note on Monday, July 6th. UBS Group reiterated a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Finally, Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $175.71.

Read Our Latest Stock Report on RGEN

Repligen Stock Down 0.7%

Shares of NASDAQ:RGEN opened at $178.71 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $198.87. The stock has a 50-day simple moving average of $176.92 and a 200-day simple moving average of $147.46. The stock has a market capitalization of $10.09 billion, a P/E ratio of 91.38, a PEG ratio of 3.28 and a beta of 1.08.

Repligen (NASDAQ:RGEN – Get Free Report) last posted its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current year.

About Repligen

(Free Report)

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

Featured Articles

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN – Free Report).